Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurobiology of Disease

• Publication date

  2015-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.nbd.2014.11.007PMID 25449909PMCID PMC4882765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

  2014cited by this paper
• Chronic Administration of Anti-Stroke Herbal Medicine TongLuoJiuNao Reduces Amyloidogenic Processing of Amyloid Precursor Protein in a Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Yin and Yang of ginseng pharmacology: ginsenosides vs gintonin

  2013cited by this paper
• A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system

  2013cited by this paper
• 100 years of Lewy pathology

  2013cited by this paper
• Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action

  2012cited by this paper
• Effects of Panax ginseng in Neurodegenerative Diseases

  2012cited by this paper
• Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

  2012cited by this paper
• Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells.

  2012cited by this paper
• Inhibition and disaggregation of α‐synuclein oligomers by natural polyphenolic compounds

  2011cited by this paper
• Ginsenosides and Their CNS Targets

  2011cited by this paper
• Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.

  2011cited by this paper
• Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease.

  2011cited by this paper
• Biological Activities of Ginseng and Its Application to Human Health -- Herbal Medicine: Biomolecular and Clinical Aspects

  2011cited by this paper
• Biological Activities of Ginseng and Its Application to Human Health

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• Mechanism of membrane interaction and disruption by α-synuclein.

  2011cited by this paper
• Ginsenoside Rb1 protects PC12 cells against β-amyloid-induced cell injury.

  2010cited by this paper
• Ginsenoside Rg1 Attenuates Amyloid-β Content, Regulates PKA/CREB Activity, and Improves Cognitive Performance in SAMP8 Mice

  2010cited by this paper
• Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils—current status

  2010cited by this paper
• American ginseng: potential structure-function relationship in cancer chemoprevention.

  2010cited by this paper
• Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity*

  2010cited by this paper
• Ginseng compounds: an update on their molecular mechanisms and medical applications.

  2009cited by this paper
• Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity

  2009cited by this paper
• Protective effect of ginsenoside Rb1 on β-amyloid protein(1-42)-induced neurotoxicity in cortical neurons

  2009cited by this paper
• Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

  2008cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

  2007cited by this paper
• Neuroprotective effects of ginsenoside Rg3 against homocysteine-induced excitotoxicity in rat hippocampus.

  2007cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• [Ginsenoside Rb1 attenuates beta-amyloid peptide(25-35) -induced hyperphosphorylation of tau protein through CDK5 signal pathway].

  2007cited by this paper
• Reductions in levels of the Alzheimer's amyloid β peptide after oral administration of ginsenosides

  2006cited by this paper
• Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng.

  2006cited by this paper
• Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism

  2006cited by this paper
• An in vitro Study

  2005cited by this paper
• Heat Shock Protein 70 Inhibits α-Synuclein Fibril Formation via Preferential Binding to Prefibrillar Species*

  2005cited by this paper
• Aβ(25–35)-Induced Memory Impairment, Axonal Atrophy, and Synaptic Loss are Ameliorated by M1, A Metabolite of Protopanaxadiol-Type Saponins

  2004cited by this paper
• A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins.

  2003influential reference
• In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes.

  2003cited by this paper
• The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

  2003cited by this paper
• Soluble oligomers for the diagnosis of neurodegenerative diseases.

  2003cited by this paper
• Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line.

  2002cited by this paper
• Conformational properties of alpha-synuclein in its free and lipid-associated states.

  2001influential reference
• Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations*

  2001cited by this paper
• Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization.

  2000cited by this paper
• Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

  2000cited by this paper
• Pathobiology of the Lewy body.

  1999cited by this paper
• Ginseng pharmacology: multiple constituents and multiple actions.

  1999cited by this paper
• Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

  1999cited by this paper
• Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease†

  1999cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments

  1998cited by this paper
• Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.

  1996cited by this paper
• Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?

  1993cited by this paper
• Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB.

  1992cited by this paper
• PATHOGENESIS AND THERAPY

  1954cited by this paper

• Mechanisms of Panax notoginseng in the treatment of vascular disease: A review and preliminary analysis

  2026cites this paper
• Interactions Between Nutraceuticals and α-Synuclein Conformational States: Molecular Mechanisms and Neuroprotective Implications in Parkinson’s Disease

  2026cites this paper
• Small-molecule-based activation of Wnt/β-catenin signaling: An underexplored yet promising strategy for neuroprotection.

  2026cites this paper
• Emerging Techniques for the Identification of Traditional Chinese Medicine-Derived Molecules Targeting Parkinson's Disease.

  2025cites this paper
• Galleria mellonella as a drug discovery model to study oxidative stress

  2025cites this paper
• The role of Panax ginseng in neurodegenerative disorders: mechanisms, benefits, and future directions

  2025cites this paper
• Sulfamerazine as a Potential Modulator against α-Synuclein Aggregation and Associated Toxicity.

  2025cites this paper
• Plant-Based Inhibitors of Protein Aggregation

  2025cites this paper
• Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth

  2025cites this paper
• Identification of Small Molecule Dimethyoxyphenyl Piperazine Inhibitors of Alpha-Synuclein Fibril Growth

  2025cites this paper
• A comprehensive review of natural compounds and their structure–activity relationship in Parkinson’s disease: exploring potential mechanisms

  2024cites this paper
• Investigating the protective properties of Panax ginseng and its constituents against biotoxins and metal toxicity: a mechanistic review

  2024cites this paper
• Effects of Red ginseng on neuroinflammation in neurodegenerative diseases

  2023cites this paper
• Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntington proteins.

  2023cites this paper
• The Molecular Basis of Wnt/β-Catenin Signaling Pathways in Neurodegenerative Diseases

  2023cites this paper
• Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease

  2023cites this paper
• Integrated Multimodal Omics and Dietary Approaches for the Management of Neurodegeneration

  2023cites this paper
• GV‐971 attenuates α‐Synuclein aggregation and related pathology

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• Screening for Novel Inhibitors of Amyloid Beta Aggregation and Toxicity as Potential Drugs for Alzheimer’s Disease

  2023influential citation
• Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases

  2023influential citation
• Identification, 3D modelling, and expression analysis of protopanaxadiol and protopanaxatriol synthases in Vietnamese ginseng under vanadium elicitation

  2023cites this paper
• The neuroprotective effect of traditional Chinese medicinal plants—A critical review

  2023cites this paper
• Exploring the Potential Therapeutic Approach Using Ginsenosides for the Management of Neurodegenerative Disorders

  2023cites this paper
• Production of α-Synuclein Fibrillar-Specific scFv from Inclusion Bodies.

  2023cites this paper
• Scorpion venom heat-resistant synthetic peptide protects dopamine neurons against 6-hydroxydopamine neurotoxicity in C. elegans.

  2022cites this paper
• Polymorphism in alpha-synuclein oligomers and its implications in toxicity under disease conditions

  2022cites this paper
• Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases

  2022cites this paper
• Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK‐3β/β‐catenin signaling pathway

  2022cites this paper
• Transcellular propagation of fibrillar α-synuclein from enteroendocrine to neuronal cells requires cell-to-cell contact and is Rab35-dependent

  2022cites this paper
• Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers

  2022cites this paper
• Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance

  2022cites this paper
• Involvement of Autophagy in the Protective Effects of Ginsenoside Rb1 in a Rat Model of Traumatic Brain Injury

  2022cites this paper
• Neurorescue Effects of Frondoside A and Ginsenoside Rg3 in C. elegans Model of Parkinson’s Disease

  2021cites this paper
• Rosmarinic Acid Potently Detoxifies Amylin Amyloid and Ameliorates Diabetic Pathology in a Transgenic Rat Model of Type 2 Diabetes.

  2021cites this paper
• Highly enhanced activity and stability via affinity induced immobilization β-glucosidase from Aspergillus niger onto amino-based silica for the biotransformation of ginsenoside Rb1.

  2021cites this paper
• Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity

  2021cites this paper
• Alpha-Synuclein: Biomarker for Parkinson’s Disease, It’s Estimation Methods, and Targeted Medicinal Therapies

  2021cites this paper
• Diterpene glycosides from Holothuria scabra exert the α-synuclein degradation and neuroprotection against α-synuclein-Mediated neurodegeneration in C. elegans model.

  2021cites this paper
• Role of ginseng in the neurovascular unit of neuroinflammatory diseases focused on the blood-brain barrier

  2021cites this paper
• Ellagic Acid Prevents α-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated α-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy

  2021cites this paper
• αSyn α-Synuclein GCase Glucocerebrosidase HMGB1 High-mobility group box 1 MMP Mitochondrial membrane permeabilization mPTP Mitochondrial permeability transition pore RPCT Randomized, placebo-controlled trial TSPO The outer membrane translocator protein 18 kDa UPDRS Unified Parkinson’s Disease Rating

  2021cites this paper
• Disease-modifying treatment of Parkinson’s disease by phytochemicals: targeting multiple pathogenic factors

  2021cites this paper
• Recent progress (2015–2020) in the investigation of the pharmacological effects and mechanisms of ginsenoside Rb1, a main active ingredient in Panax ginseng Meyer

  2021cites this paper
• Strategies for the potential treatment of neurological disorders with Chinese and Indian medicinal plants

  2021cites this paper
• Crocin Inhibits the Fibrillation of Human α-synuclein and Disassembles Mature Fibrils: Experimental Findings and Mechanistic Insights from Molecular Dynamics Simulation.

  2021cites this paper
• Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity

  2020cites this paper
• Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

  2020cites this paper
• Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts

  2020cites this paper
• Non-polyphenolic natural inhibitors of amyloid aggregation.

  2020cites this paper
• Nutraceuticals: An integrative approach to starve Parkinson’s disease

  2020cites this paper
• Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges

  2020cites this paper
• Panax ginseng Meyer Herbal Preparation

  2020cites this paper
• Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies

  2020cites this paper
• Protective effects of four new saponins from Gynostemma pentaphyllum against hydrogen peroxide-induced neurotoxicity in SH-SY5Y cells.

  2020cites this paper
• Catechol-Containing Compounds are a Broad Class of Protein Aggregation Inhibitors: II. Rosmarinic Acid Potently Detoxifies Amylin Amyloid and Ameliorates Diabetic Pathology in HIP Rats

  2020cites this paper
• PHYTOCHEMICALS AS FUTURE DRUGS FOR PARKINSON’S DISEASE: A REVIEW

  2020cites this paper
• Anti-Parkinson activity of bioactive substances extracted from Holothuria leucospilota.

  2019cites this paper
• Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson’s Disease Models

  2019cites this paper
• Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein

  2019cites this paper
• Enhanced mitochondrial inhibition by 3,4‐dihydroxyphenyl‐acetaldehyde (DOPAL)‐oligomerized α‐synuclein

  2019cites this paper
• Neuroprotective Effects of Ginseng Phytochemicals: Recent Perspectives

  2019cites this paper
• Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates α-synuclein aggregation in vitro.

  2019cites this paper
• Ginsenoside Rb1 prevents MPTP-induced changes in hippocampal memory via regulation of the α-synuclein/PSD-95 pathway

  2019cites this paper
• Terpenoids in Treatment of Neurodegenerative Disease

  2019cites this paper
• Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models

  2019influential citation
• Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.

  2019cites this paper
• Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology

  2019cites this paper
• Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice

  2019cites this paper
• Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy

  2019cites this paper
• Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection

  2019cites this paper
• Antibodies against alpha‐synuclein: tools and therapies

  2019cites this paper
• Harnessing neuroplasticity: modern approaches and clinical future

  2018cites this paper
• Estrogen receptor‐β of microglia underlies sexual differentiation of neuronal protection via ginsenosides in mice brain

  2018cites this paper
• Discovery and Mechanisms of Small Molecule Amyloid Formation Inhibitors

  2018cites this paper
• Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease

  2018cites this paper
• Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.

  2017cites this paper
• Proteomic change by Korean Red Ginseng in the substantia nigra of a Parkinson's disease mouse model

  2017cites this paper
• Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing

  2017cites this paper
• Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins.

  2017cites this paper
• Comparison of disaggregative effect of A-type EGCG dimer and EGCG monomer on the preformed bovine insulin amyloid fibrils.

  2017cites this paper
• Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism

  2017cites this paper
• Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

  2017cites this paper
• Effects of saffron and its constituents, crocin-1, crocin-2, and crocetin on α-synuclein fibrils

  2017cites this paper
• Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions

  2017cites this paper
• Ginsenoside Rb1, a novel activator of the TMEM16A chloride channel, augments the contraction of guinea pig ileum

  2017cites this paper
• Natural product-based amyloid inhibitors.

  2017cites this paper
• Emerging preclinical pharmacological targets for Parkinson's disease

  2016cites this paper
• Phytochemicals as future drugs for Parkinson’s disease: a comprehensive review

  2016cites this paper
• Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

  2016cites this paper
• Determination of American ginseng saponins and their metabolites in human plasma, urine and feces samples by liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.

  2016cites this paper
• Modulating the Amyloidogenesis of α-Synuclein

  2016cites this paper
• Ginsenoside Rg1 exerts a protective effect against Aβ₂₅₋₃₅-induced toxicity in primary cultured rat cortical neurons through the NF-κB/NO pathway.

  2016cites this paper
• Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease.

  2016cites this paper
• Ginsenoside Rb1 as a neuroprotective agent: A review.

  2016cites this paper
• Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression

  2016cites this paper
• Anticancer and Antineurodegenerative Effects of Ginsenosides

  2016cites this paper
• Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

  2015cites this paper